CCG.ai begins journey with Merck

February 14, 2020

CCG.ai begins journey with Merck

Accelerator aims to establish collaborations and partnerships between startups and Merck

Cambridge Cancer Genomics (CCG.ai), a Y Combinator backed startup building the software to enable data-driven personalised cancer medicine, today announced its participation in The Merck Accelerator.

CCG.ai - a startup on a mission to ensure that each patient has the right drug, at the right time, to beat their cancer - were selected alongside 11 other startups, from 503 applicants, across 65 countries. More than 200 Merck experts with a variety of specialisms were involved in the strategic selection of the 12 startups with the highest potential for collaboration.

Merck, a leading science and technology company, designed the accelerator (now in its 8th intake) to establish collaborations and partnerships between startups and Merck, creating a win-win situation for both parties. CCG.ai’s participation in the programme will allow them to work closely with Merck’s highly experienced team to co-create, conduct pilot projects and run proof of concepts. The collaboration will hopefully lead to both companies becoming first movers in the field of data-driven precision oncology. 

Dr. John Cassidy, CEO of Cambridge Cancer Genomics, says: “We believe that uniting AI with clinical and genomic data has the potential to transform cancer treatment, and are incredibly excited to have the opportunity to work closely with Merck: their wealth of experience in bringing science and health technologies to market will be immensely valuable in getting our technology into the hands of those that will most benefit from it.”

Each team will receive individual support and coaching from experts within the Merck network, as well as up to €50,000 in funding and the opportunity to join the Merck China Innovation Hub in Shanghai for an extension of the program. 

Munya Chivasa, Head of the Merck Accelerator adds: “Working with startups has brought numerous opportunities to different areas of Merck and we are constantly adapting and evolving these programs to make them even more fruitful for both sides. We are delighted with the exceptionally high quality of the startups that have been selected for the Merck Accelerator’s 8th intake at the Merck Innovation Center and we wish them all the best and lots of collaborations in this new phase!”

The full list of participating teams are available to view here.


--

About Cambridge Cancer Genomics

Cambridge Cancer Genomics (CCG.ai) are on a mission to ensure that each patient has the right drug, at the right time, to beat their cancer. We build the software to enable data-driven precision oncology and systematically develop data-driven biomarkers indicative of treatment response.

We believe that increasing amounts of clinical and genomic data have the potential to transform cancer treatment, and enable oncologists to make smarter decisions about which drug to use in which circumstance.

Find out more at www.ccg.ai

Press Enquiries

For more details, or to request an interview, please contact Press@CCG.ai